Jiangxi Xinganjiang Pharmaceutical CoBJSE:920367 60 Interest Coverage is 539.40 as of Mar. 2026, which is 362% above its 10-year median of 116.66. GuruFocus rates BJSE:920367 with a GF Score™ of 60/100 and a GF Value™ of ¥12.11 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 685 Drug Manufacturers companies, Jiangxi Xinganjiang Pharmaceutical Co ranks better than 90.95% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Jiangxi Xinganjiang Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥2.7 Mil. Jiangxi Xinganjiang Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-0.0 Mil.
Jiangxi Xinganjiang Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 539.40.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Jiangxi Xinganjiang Pharmaceutical Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
BJSE:920367'
s Interest Coverage Range Over the Past 10 Years
Min: 10.27 Med: 116.66 Max: 1103.44
Current: 535.57
BJSE:920367's Interest Coverage is ranked better than 90.95% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BJSE:920367: 535.57
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Jiangxi Xinganjiang Pharmaceutical Co Interest Coverage Related Terms
Jiangxi Xinganjiang Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Jiangxi Xinganjiang Pharmaceutical Co Interest Coverage Chart
BJSE:920367 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangxi Xinganjiang Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Xinganjiang Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangxi Xinganjiang Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Jiangxi Xinganjiang Pharmaceutical Co's Interest Coverage falls into.
Jiangxi Xinganjiang Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) has a Interest Coverage of 539.40 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. This is 362% above median its historical median of 116.66. Over the past decade, Jiangxi Xinganjiang Pharmaceutical Co's Interest Coverage has ranged from 10.27 to 1,103.44. According to the industry distribution chart, Jiangxi Xinganjiang Pharmaceutical Co ranks #62 out of 685 companies in the Drug Manufacturers industry, placing it in the top 9.1%.
Is Jiangxi Xinganjiang Pharmaceutical Co's Interest Coverage too high?
Jiangxi Xinganjiang Pharmaceutical Co's current Interest Coverage of 539.40 is 362% above median its 10-year median of 116.66. Over the past 10 years, this metric has ranged from a low of 10.27 to a high of 1,103.44. The Drug Manufacturers industry median Interest Coverage is 12.75. Jiangxi Xinganjiang Pharmaceutical Co's value of 539.40 is 4130.6% above this industry median. Based on the distribution chart, Jiangxi Xinganjiang Pharmaceutical Co ranks #62 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangxi Xinganjiang Pharmaceutical Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Xinganjiang Pharmaceutical Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangxi Xinganjiang Pharmaceutical Co ranks #62 out of 685 companies for Interest Coverage. This places Jiangxi Xinganjiang Pharmaceutical Co in the top 9% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Jiangxi Xinganjiang Pharmaceutical Co's value of 539.40 is 4130.6% above this benchmark. Historically, Jiangxi Xinganjiang Pharmaceutical Co's own Interest Coverage has ranged from 10.27 to 1,103.44 over the past decade. While the company's 10-year median is 116.66 vs. the industry median of 12.75, Jiangxi Xinganjiang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Xinganjiang Pharmaceutical Co's current Interest Coverage of 539.40 is 4130.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Xinganjiang Pharmaceutical Co's current Interest Coverage is 539.40, which is 362% above median its own 10-year median of 116.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Xinganjiang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥12.11, compared to a current price of ¥22.50 — trading 85.8% above its estimated fair value. The current Interest Coverage is 539.40, which is 362% above median its 10-year median of 116.66 and 4130.6% above the Drug Manufacturers industry median of 12.75. Jiangxi Xinganjiang Pharmaceutical Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367), the current Interest Coverage is 539.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥22.50 is trading 85.8% above its estimated GF Value™ of ¥12.11.
GuruFocus considers Jiangxi Xinganjiang Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for BJSE:920367:
Interest Coverage: 539.40 (362% above median its 10-year median of 116.66)
GF Value™: ¥12.11 vs. price of ¥22.50 (85.8% above fair value)
Industry Position: 4130.6% above the Drug Manufacturers median (#62 of 685)
No single metric tells the full story. See the BJSE:920367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangxi Xinganjiang Pharmaceutical Co Business Description
Jiangxi Xinganjiang Pharmaceutical Co Ltd conducts research and development, production, and sales of chemical raw materials, chemical preparations, and Chinese patent medicines. The company's raw material medicine products are mainly calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw material medicines. Its main chemical preparations are vitamin C chewable tablets and compound Yinqiao aminomin capsules, and Phenaminokamin Tablets.
60GF Score
Get the complete analysis for BJSE:920367
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920367 has been successfully added to your 
